Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

Vinod P. Shah, K.K. Midha, S Dighe et al. · European Journal of Drug Metabolism and Pharmacokinetics · 1991 · 615 citations

Analytical Methods Validation, Medicine, Bioanalysis +2

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 430 citations

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.

Sylvia S. W. Ng, Ming‐Sound Tsao, Trudey Nicklee et al. · PubMed · 2002 · 165 citations

Downstream Signaling Pathways, Cell Death, Pathology +17

Sensitive determination of docetaxel in human plasma by liquid–liquid extraction and reversed-phase high-performance liquid chromatography

Walter J. Loos, Jaap Verweij, Kees Nooter et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1997 · 77 citations

Therapeutic Drug Monitoring, Bioanalysis, Pharmacology +11